If the medicine Remdesivir be given at the right time, it can reduce the coronadødeligheden with about 80 percent
It shows the data from a new study published in the New England Journal of Medicine, writes Politiken Friday.
Professor of communicable diseases Jens Lundgren from copenhagen university hospital points out to the newspaper that there is talk about the preliminary data. But he is surprised by how significant the effect of the drug seems to be.
however, This only applies if Remdisivir be given before the patient ends up in the respirator, and 'at the right time', he explains.
When I saw the data ... it is the whole game. It changes completely in the paradigm of how we must attack this disease. When we need to put in, and what we should do with icu patients, says Jens Lundgren to Politiken.
the Newspaper writes that, treatment was initiated about the time when ilttilskud began to be necessary, he died in the attempt as few as 2.4 percent covid-19-ill, who got Remdesivir'. In actual figures, this corresponds to 4 out of 222 patients.
Meanwhile, it was 10,9 percent of those who did not receive treatment, as the dead - or 19 out of 199 patients in the placebo group.
For people who suspect that it's going in the wrong direction during the disease, shows it is clear that they must respond, points out Jens Lundgren.
- thus, It is really important that you get hold of a doctor if you after some days, with increasing disease experience deterioration. On average, it happens six days after the onset of symptoms. We are experiencing, unfortunately, a part coronapatienter, coming in late, because the they have been too long at home, he says to Politiken.
Data come from a large, international trial, where Jens Lundgren sits as the chairman of the european section.
another researcher - Anton Pottegård, professor at the Department of Clinical Pharmacology and Pharmacy, University of Southern denmark - says to Politiken, however, there still lacks data on the side effects of the medicine.
the Drug is not yet approved for the treatment of Covid-19-patients.
The European medicines Agency (EMA) announced however Monday that it was close to a conditional approval.
Remdesivir was developed in 2009 for the treatment of hepatitis C and as a possible remedy against virussygdommen ebola.
the UNITED states approved 1. may Remdesivir to nødbehandling of coronasyge.